Sellas Stock Rises as Regal Trial Hits Final Analysis
Sellas Life Sciences shares edged higher after its Phase 3 Regal trial reached the milestone that triggers final analysis.
Updated on Nov. 10, 2026 in Economic Indicators
Sellas Life Sciences Group stock rose nearly 1% overnight heading into Tuesday. The Regal trial reached its pre-specified 80th event, triggering the final analysis of the Phase 3 study.
Why it matters
The Regal trial evaluates Galinpepimut-S as maintenance treatment for acute myeloid leukemia patients in second complete remission, using overall survival as its primary endpoint. Reaching the event threshold moves the program toward a key data readout that investors and patients are watching closely.
Sellas reported a Q2 net loss of $9.6 million and $138.3 million in cash and equivalents as of June 30, against analyst expectations of a $0.05 loss per share versus $0.07 a year earlier. The Regal trial's efficacy outcome remains unknown until topline results arrive, expected in the fourth quarter.
The players
Sellas Life Sciences Group
Sellas Life Sciences Group is a clinical-stage biopharmaceutical company developing cancer therapies, including Galinpepimut-S for acute myeloid leukemia.
The details
Regal reached its pre-specified 80th event, which triggers the final analysis under the trial design. Next steps include database lock, unblinding and statistical analysis before results are released.
Timeline
June 30: Sellas reported $138.3 million in cash and equivalents.
Monday, Nov. 9, 2026: SLS stock climbed nearly 2% and is up 128% year-to-date.
Tuesday, Nov. 10, 2026: Quarterly update expected, with analysts projecting a $0.05 loss per share.
Q4 2026: Regal topline results and SLS009 frontline data expected.
Dec. 14, 2026: Previously treated AML data scheduled for presentation at ASH.
Economic Indicators
Biotech small caps like Sellas trade on trial milestones rather than traditional revenue, so stock moves reflect investor expectations about pipeline outcomes. The 128% year-to-date gain shows how sensitive these shares remain to clinical progress and capital-raising conditions.
Retail investors holding small-cap biotech shares face large swings tied to trial timing rather than earnings, so position sizing matters. The Q4 readout could move the stock sharply in either direction, with no revenue currently offsetting a projected quarterly operating loss near $10.42 million.
The takeaway
Clinical milestones, not quarterly losses, drive biotech valuations, so the Regal readout in Q4 is the event to watch. Investors should weigh cash runway of $138.3 million against ongoing losses before reacting to near-term price moves.
What happens next
Regal topline results are expected in Q4 2026, followed by frontline SLS009 data and previously treated AML data presented at ASH on Dec. 14, 2026.
Further reading
Track broader market signals in the Economic Indicators section for context on how investors price biotech stocks.
